Author:
Calvo Emiliano,Reddy Guru,Boni Valentina,García-Cañamaque Lina,Song Tao,Tjornelund Jette,Choi Mi Rim,Allen Lee F.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference11 articles.
1. Qian X, LaRochelle WJ, Ara G, et al. (2006) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5(8):2086–2095
2. Plumb JA, Finn PW, Williams RJ, et al. (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel deacetylase inhibitor PXD101. Mol Cancer Ther 2(8):721–728
3. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769–784
4. O’Connor OA, Horwitz S, Masszi T, et al. (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33:2492–2499
5. Steele NL, Plumb JA, Vidal L, et al. (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14(3):804–810
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献